Table 2.
Quality of evidence is weaker if comparisons in trials are indirect
| Question of interest | Source of indirectness |
|---|---|
| Relative effectiveness of alendronate and risedronate in osteoporosis | Indirect comparison: randomised trials have compared alendronate with placebo and risedronate with placebo, but trials comparing alendronate with risedronate are unavailable |
| Oseltamivir for prophylaxis of avian flu caused by influenza A (H5N1) virus | Differences in population: randomised trials of oseltamivir are available for seasonal influenza, but not for avian flu |
| Sigmoidoscopic screening for prevention of mortality from colon cancer | Differences in intervention: randomised trials of faecal occult blood screening provide indirect evidence, bearing on potential effectiveness of sigmoidoscopy |
| Choice of drug for schizophrenia | Differences in comparator: series of trials comparing newer generation neuroleptic agents with fixed doses of haloperidol 20 mg provide indirect evidence of how newer agents would compare with lower, flexible doses of haloperidol that clinicians typically use |
| Rosiglitazone for prevention of diabetic complications in patients at high risk of diabetes | Differences in outcome: randomised trial shows delay in development of biochemical diabetes with rosiglitazone but was underpowered to tackle diabetic complications |